33208-47-8

Usage

Uses

Used in Pharmaceutical Industry:
.beta.-D-Mannopyranose, 1,6:2,3-dianhydro-4-O-(phenylmethyl)is used as a key component in the development of pharmaceutical compounds due to its unique chemical structure. The modification of the mannose molecule may enhance its interaction with biological targets, potentially leading to the development of new drugs with improved efficacy and selectivity.
Used in Chemical Synthesis:
In the field of chemical synthesis, .beta.-D-Mannopyranose, 1,6:2,3-dianhydro-4-O-(phenylmethyl)can be used as a starting material or intermediate for the synthesis of complex organic molecules. The presence of the phenylmethyl group and the dianhydro ring formation may facilitate specific chemical reactions, allowing for the creation of novel compounds with diverse applications.
Used in Material Science:
The unique structure of .beta.-D-Mannopyranose, 1,6:2,3-dianhydro-4-O-(phenylmethyl)may also find applications in material science, where it could be used to develop new materials with specific properties. For example, its incorporation into polymers could result in materials with enhanced mechanical strength, thermal stability, or biological compatibility.
Used in Research and Development:
As a novel chemical entity, .beta.-D-Mannopyranose, 1,6:2,3-dianhydro-4-O-(phenylmethyl)can be utilized in research and development to explore its potential applications and properties. This may include studies on its biological activity, chemical reactivity, and potential use in various industries, such as pharmaceuticals, chemical synthesis, and material science.

Upstream product

• 40838-18-4 1,6-anhydro-4-O-benzyl-2,3-dideoxy-β-D-erythro-hex-2-enopyranose 
• 20183-65-7 1,6-anhydro-4-O-benzyl-2-O-(4-toluenesulfonyl)-β-D-glucopyranose 
• 100-39-0 benzyl bromide 
• 139437-39-1 1,6-anhydro-2-deoxy-2-iodo-β-D-glucopyranose 
• 50767-55-0 1,6-anhydro-4-O-benzyl-2-iodo-2-deoxy-β-D-glucopyranose 
• 2873-29-2 D-glucal triacetate 
• 161365-77-1 1,6-anhydro-2-chloro-β-D-erythro-hex-3-enopyranose 
• 50705-28-7 1,6-anhydro-3,4-dideoxy-β-D-threo-hex-3-enopyranose 
• 13265-84-4 D-glucal 
• 3868-03-9 1,6:2,3-dianhydro-β-D-mannopyranose 
• 110046-93-0 1,6-anhydro-4-O-benzyl-2-bromo-2-deoxy-β-D-glucopyranose 
• 75316-80-2 1,6-anhydro-4-O-benzyl-3-O-(N-benzylcarbamoyl)-2-O-p-tolylsulfonyl-β-D-glucopyranose 
• 148473-54-5 Acetic acid (1R,2R,3S,4R,5R)-2-benzyloxy-4-bromo-6,8-dioxa-bicyclo[3.2.1]oct-3-yl ester 
• 58394-31-3 1,6-anhydro-2,3-dideoxy-β-D-erythro-hex-2-enopyranose 

Downstream Products

• 129797-11-1 1,6-anhydro-4-O-benzyl-2-deoxy-2-C-vinyl-β-D-glucopyranose 
• 104206-20-4 1,6-anhydro-4-O-benzyl-2-chloro-2-deoxy-β-D-glucopyranose 
• 104206-19-1 1,6-anhydro-4-O-benzyl-2-deoxy-2-C-(2-propenyl)-β-D-glucopyranose 
• 110046-81-6 1,6-anhydro-4-O-benzyl-2-deoxy-2-C-(3-tert-butyldimethylsilyloxyprop-1-ynyl)-β-D-glucopyranose 
• 65190-43-4 4-O-benzyl-2-methyl-1,6-anhydro-β-D-glucopyranose 
• 129797-10-0 (1R,2S,3R,4R,5R)-2-Benzyloxy-4-trimethylsilanylethynyl-6,8-dioxa-bicyclo[3.2.1]octan-3-ol 
• 129797-08-6 (4aR,6S,7S,8S,8aS)-7-[3-(tert-Butyl-dimethyl-silanyloxy)-prop-1-ynyl]-6-methoxy-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-8-ol 
• 89731-34-0 1,6-anhydro-4-O-benzyl-2-deoxy-2-C-(3-hydroxypropynyl)-β-D-glucopyranose 
• 117844-35-6 1,6-anhydro-4-O-benzyl-2-O-(prop-2-ynyl)-β-D-glucopyranose 
• 110046-91-8 1,6-anhydro-4-O-benzyl-2C-<3'-<(tert-butyldimethylsilyl)oxy>-2'-methylprop-1'(Z)-enyl>-β-D-glucopyranose 
• 110046-94-1 (1R,2S,3R,4R,5R)-2-Benzyloxy-4-((Z)-3-methoxymethoxy-2-methyl-propenyl)-6,8-dioxa-bicyclo[3.2.1]octan-3-ol 
• 40838-18-4 1,6-anhydro-4-O-benzyl-2,3-dideoxy-β-D-erythro-hex-2-enopyranose 
• 55682-47-8 1,6-anhydro-2-azido-4-O-benzyl-2-deoxy-β-D-glucopyranose 
• 110046-93-0 1,6-anhydro-4-O-benzyl-2-bromo-2-deoxy-β-D-glucopyranose 

Relevant academic research and scientific papers

AN EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM

The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds.

Structure and stereochemistry of an anti-inflammatory anhydrosugar from the Australian marine sponge Plakinastrella clathrata and the synthesis of two analogues

The structure and relative/absolute configuration of the C-15:0 iso-branched fatty acyl 1,6-anhydropyranose 1 isolated from the Australian marine sponge Plakinastrella clathrata have been investigated. Synthesis of the C-16:0 side chain-modified analogues

Synthesis and glycosidase inhibitory activity of noeurostegine - A new and potent inhibitor of β-glucoside hydrolases

A new, stable hemi-aminal nor-tropane christened noeurostegine was synthesised in 22 steps from levoglucosan and tested for inhibitory activity against glycoside hydrolases. Sweet almond and Thermotoga maritimaβ- glucosidases, coffee bean α-galactosidase,

Total synthesis of n-acetylglucosamine-1,6-anhydro-n- acetylmuramylpentapeptide and evaluation of its turnover by ampd from escherichia coli

The bacterial cell wall is recycled extensively during the course of cell growth. The first recycling event involves the catalytic action of thelytic transglycosylase enzymes, which produce an uncommon 1,6-anhydropy ranose moiety during separation of the muramyl residues from the peptidoglycan, the major constituent of the cell wall. This product, an N-acetyl-β-D-glucosamine- (1→4)-1,6-anhydro-N-acetyl-β-Dmuramylpeptide, is either internalized to initiate the recycling process or diffuses into the milieu to cause stimulation of the pro-inflammatory responses by the host. We report the total syntheses of N-acetyl-β-Dglucosamine-( 1→4)-1,6-anhydro-N-acetyl- β-D-muramyl-L-Ala-γ-D-Glu-meso-DAP-D-Ala-D-Ala (compound 1, the product of lytic transglycosylase action on the cell wall of Gram-negative bacteria) and N-acetyl-β-Dglucosamine-( 1→4)-1,6-anhydro-N-acetyl- β-D-muramyl-L-Ala-γ-D-Glu-L-Lys-D-Ala-D-Ala (compound 2, from lytic transglycosylase action on the cell wall of Gram-positive bacteria). The syntheses were accomplished in 15 linear steps. Compound 1 is shown to be a substrate of the AmpD enzyme of the Gram-negative bacterium Escherichia coli, anenzyme that removes the peptide from the disaccharide scaffold in the e arly cytoplasmic phase of cell wall turnover.

A facile synthesis of Cerny epoxides and selectively blocked derivatives of 2-azido-2-deoxy-β-D-glucopyranose

1,6:2,3-Dianhydro-β-D-glucopyranose and its 3-alkylated derivatives were prepared from D-glucal in one pot with overall isolated yields of 60-70%, and these Cerny epoxides were further conveniently converted to selectively blocked 2-azido-2-deoxy-β-D-glucopyranose derivatives by azido opening of the epoxide ring.

Synthesis of 1,6-Anhydro-2-chloro-2,3,4-trideoxy-β-D-erythro-hex-3-enopyranose and its Stereospecific SN2' Substitution

The chlorination of 1,6-anhydro-3,4-dideoxy-β-D-threo-hex-3-enopyranose (2) with SOCl2 and pyridine gives predominantly 1,6-anhydro-2-chloro-β-D-erythro-hex-3-enopyranose (3).The chloride (3) takes place exclusively the suprafacial SN2' substit

PREPARATION OF 2-AMINO-1,6-ANHYDRO-2-DEOXY-β-D-MANNOPYRANOSE BY INTRAMOLECULAR SUBSTITUTION OF THE TOSYLOXY GROUP IN STERICALLY HINDERED POSITION OF 1,6-ANHYDRO-2-O-p-TOLYLSULFONYL-β-D-GLUCOPYRANOSE

1,6:3,4-Dianhydro-2-O-p-tolylsulfonyl-β-D-galactopyranose (I) was converted to 1,6-anhydro-4-O-benzyl-2-O-p-tolylsulfonyl-β-D-glucopyranose (II) and then reacted with benzylisocyanate to give 3-O-(N-benzylcarbamoyl) derivative III.The cyclization of this